Interim analysis of the Phase 2b results shows a dose-proportional decrease in the ototoxicity rate. Currently, there are no FDA-approved therapies for the prevention/treatment of aminoglycoside ototoxicity or the treatment of any other type of sensorineural hearing loss, tinnitus, or dizziness.
Sound Pharmaceuticals to Present Positive Interim Data from its Phase 2b Cystic Fibrosis STOP Ototoxicity Trial
Share: